Compare Hims and Hers Health Inc (HIMS) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Nutanix Inc — how do they compare? Hims and Hers Health Inc trades at $29.95 (market cap $7.12B), while Nutanix Inc trades at $64.52 (market cap $17.39B). The key difference: Nutanix Inc is far larger — about 2.4× Hims and Hers Health Inc's market cap, and Nutanix Inc is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals.
| HIMS | NTNX | |
|---|---|---|
Market Cap | $7.12B | $17.39B |
Sector | Health | Technology |
52-Week High | $62.76 | $81.12 |
52-Week Low | $14.52 | $34.41 |
Enterprise Value | $7.82B | $16.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HIMS stock trades at $29.97, down 5.67% amid mixed Q2 2026 results. Revenue growth remains strong with a 2026 outlook raised to $3.1B-$3.3B, but profitability is pressured by margin compression and a net loss. Technical indicators are neutral to bearish, with support near $29. Recent news highlights an FTC investigation and class-action lawsuits adding uncertainty.
The outlook is cautious. Growth prospects from AI and global expansion are offset by significant margin challenges and regulatory risks. Analyst consensus is a Hold with a $33 price target, suggesting limited near-term upside amid execution and profitability concerns.
Nutanix (NTNX) trades at $64.65, up 0.29% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $0.47 versus $0.36, maintaining a streak of earnings surprises. Revenue growth accelerated to $2.7B in 2026 with net profit margin expanding to 10.03%, while institutional interest remains strong with recent acquisitions by Arrowstreet Capital and CalPERS.
Outlook remains positive with 62.5% analyst buy ratings and a $57.80 consensus target, though current price exceeds this level. Key risks include supply chain constraints affecting hardware lead times and competitive pressure in cloud infrastructure. The stock's elevated P/E of 67.71 requires continued execution to justify valuation, with Q2 2026 earnings on August 26th serving as near-term catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
